MOLN

Molecular Partners AG

4.30 USD

Last updated Dec 8, 15:38 UTC

Yesterday HIGH

$4.61

Yesterday LOW

$4.15

52w HIGH

$7.36

52w LOW

$3.53

EPS

-1.05

PE

-4.10

Next Earnings

Mar 7, 2024

Overview News Government Trades

Molecular Partners AG stock is down -2.71% since 30 days ago. The next earnings date is Mar 7, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 100% of the previous 2 December’s closed higher than November. 0% of analysts rate it a buy.

Molecular Partners AG focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema. MP0420 is a multi-specific DARPin therapy candidate for the SARS-CoV-2 virus. The company also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

-

Website

molecularpartners.com

Benzinga Insights

Thu Sep 7, 2023

Stocks That Hit 52-Week Lows On Thursday

On Thursday, 283 companies set new 52-week lows.
Happy Mohamed

Thu Aug 24, 2023

CORRECTION: Molecular Partners H1 EPS $(1.05) Down From $4.86 YoY, Sales $3.85M Down From $195.55M YoY

Molecular Partners (NASDAQ:MOLN) reported quarterly losses of $(1.05) per share. This is a 121.6 percent decrease over earnings of $4.86 per share from the same period last year. The company reported $3.85 million in
Happy Mohamed

Thu Aug 24, 2023

Molecular Partners H1 EPS $(1.05) Down From $4.86 YoY, Sales $3.85M Down From $195.55M YoY

Molecular Partners (NASDAQ: MOLN) reported quarterly losses of $(1.05) per share. This is a 121.6 percent decrease over earnings of $4.86 per share from the same period last year. The company reported $3.85 million in sales this quarter. This is a 98.03 percent decrease over sales of $195.55 million the same period last year.
Benzinga Newsdesk

Thu May 25, 2023

Molecular Partners To Present Data From Ongoing Phase 1 Trial Of MP0317 Monotherapy In Patients With Advanced Solid Tumors At 2023 ASCO Meeting
Benzinga Insights

Thu Mar 9, 2023

Earnings Scheduled For March 9, 2023

Companies Reporting Before The Bell • Aurora Mobile (NASDAQ:JG) is expected to report earnings for its fourth quarter.
Benzinga Newsdesk

Tue Dec 13, 2022

Reported Late Monday, Molecular Partners Presents New Preclinical Data Supporting Its MP0533 DARPin T-Cell Engager For The Treatment Of AML

New data indicates potential to expand the therapeutic window and improve safety compared to existing T-cell engagers Tri-specific T-cell engager resulted in AML cell-specific cytotoxicity with minimal
Benzinga Newsdesk

Thu Nov 10, 2022

Molecular Partners Presents Interim Safety And Mechanistic Data From Ongoing Phase 1 Trial Of MP0317 For Treatment of Solid Tumors

First clinical observation of tumor localized CD40 activation provided by MP0317 No systemic or dose-limiting toxicities observed, a key parameter for CD40 agents Dose escalation remains ongoing with study
Benzinga Insights

Mon Oct 10, 2022

12 Health Care Stocks Moving In Monday's Pre-Market Session

Gainers NeuroMetrix (NASDAQ:NURO) shares increased by 23.0% to $3.48 during Monday's pre-market session. The company's market cap stands at $24.8 million.
Benzinga Insights

Tue Sep 6, 2022

Stocks That Hit 52-Week Lows On Tuesday

On Tuesday, 400 companies set new 52-week lows.
Benzinga Insights

Thu Sep 1, 2022

Stocks That Hit 52-Week Lows On Thursday

On Thursday, 529 companies set new 52-week lows.